

FINE FOODS DEBUTS ON THE MAIN MARKET: 12 JULY 2021 – FIRST TRADING DAY ON THE MTA - STAR SEGMENT

BORSA ITALIANA LISTS FINE FOODS ORDINARY SHARES ON THE MTA - STAR SEGMENT

Verdellino (BG), 8 July 2021

Fine Foods & Pharmaceuticals N.T.M. S.p.A. ("**Fine Foods**" or the "**Company**") announces that today Borsa Italiana S.p.A. has issued a notice listing the Company's ordinary shares on the **STAR segment** of Mercato Telematico Azionario ("MTA") organised and managed by Borsa Italiana S.p.A. and their simultaneous exclusion from AIM Italia, **as of 12 July 2021**.

The Listing Prospectus relating to the ordinary shares listing on the MTA - STAR segment is available to the public at the Company's registered office in Zingonia - Verdellino, Via Berlino no. 39, and on the Company's website www.finefoods.it, Investor Relations / IPO section.

In the translisting process to the MTA - STAR segment, the Company was assisted by Banca Akros, as Issuer Sponsor, by Grimaldi Studio Legale as Issuer legal advisor and by Pavia e Ansaldo Studio Legale as Sponsor legal advisor. EY acted as an auditing firm, and Epyon was the consultant who checked the non-accounting data in the Listing Prospectus.

This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.

Fine Foods & Pharmaceuticals N.T.M. S.p.A. is an Italian independent CDMO (Contract Development and Manufacturing Organisation). It develops and manufactures contract products for the pharmaceutical and nutraceutical industry; the Fine Foods Group is also active in the cosmetics, biocides and medical devices industries with its recent acquisition of Pharmatek-PMC.

Founded in 1984, from a pharmaceutical and nutraceutical synergy, Fine Foods has been pursuing quality and innovation on behalf of its customers as its primary objective. With € 172 million revenue in 2020 and an 11 per cent CAGR over the last decade, it is a growing and future-oriented company.

The sustainability of the business model and the holistic approach to ESG, together with product innovation, are drivers that will allow the Group to fully develop its intrinsic potential.

For information:

Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Investor Relations

tel. +39 035 4821382

ir@finefoods.it

Banca Akros S.p.A.

Nomad

Viale Eginardo 29, Milan

ecm@bancaakros.it

CDR Communication

IR Advisor

Paola Buratti

paola.buratti@cdr-communication.it

Media Relations

Marianna Tremolada

marianna.tremolada@cdr-communication.it